When Statins Aren't Enough, This Drug May Help Lower 'Bad' Cholesterol

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 8, 2025.

By I. Edwards HealthDay Reporter

THURSDAY, May 8, 2025 — A new drug combo lowers "bad" LDL cholesterol for people whose levels remain high even after taking statins.

The new pill pairs a new drug called obicetrapib with an existing one, ezetimibe. In a Phase 3 clinical trial, this combo reduced LDL levels by nearly 49% over about three months, according to Cleveland Clinic researchers.

The results were presented Wednesday at the European Atherosclerosis Society meeting in Glasgow, Scotland, and simultaneously published in The Lancet.

“High LDL is one of the leading risk factors for heart disease, and we have such a poor handle on controlling that risk,” Dr. Corey Bradley, a cardiologist at Columbia University, told NBC News. “Many people have such a high LDL they will require multiple agents to control it.”

The trial included 407 people with an average age of 68. Even though they were taking cholesterol-lowering medications, everyone had LDL levels above 70 mg/dL. Researchers divided participants into four groups: One took the combo pill; two groups took each drug separately; and another group took a placebo. All participants continued their usual cholesterol medications.

Dr. Ashish Sarraju, a preventive cardiologist at the Cleveland Clinic, led the study.

“We need to give patients and their doctors all the options we can to try to get LDL under control if they are at risk for, or already have, cardiovascular disease,” Sarraju said. “In higher-risk patients, you want to get LDL down as quickly as possible and keep it there as long as possible.”

High-risk patients are those who have had a stroke or heart attack, or are likely to have one. Even high-intensity statins are sometimes not enough to bring LDL to safe levels.

The American Heart Association (AHA) recommends keeping LDL below 100 mg/dL — and under 70 mg/dL for high-risk patients.

The trial was funded by NewAmsterdam Pharma, the Dutch company that makes obicetrapib. The company plans to speak with the U.S. Food and Drug Administration (FDA) “over the course of the year,” about possible approval of the combo drug, a spokesperson told NBC News.

In the past, some similar drugs have not worked. Dr. Robert Rosenson of Mount Sinai Health System noted that some drugs in this class have failed to prevent strokes or heart attacks. “But I am cautiously hopeful,” he said.

NewAmsterdam Pharma is now running another trial to see if the combo drug not only lowers cholesterol but also protects against major heart events.

While lifestyle changes like eating healthy, exercising and avoiding smoking can help lower LDL, many people still struggle to reach safe levels. Only about 20% of patients are able to manage their LDL, said Bradley, of Columbia.

Sources

  • NBC News, May 7, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-05-09 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords